Tinzaparin Is Safe and Effective in the Management of Hemodialysis Catheter Thrombosis

Quinlan, Catherine; Bates, Marie; Cotter, Maura B.; Riordan, Michael; Waldron, Mary; Awan, Atif

doi:10.1097/mat.0b013e31824c38c8

Cited by 6 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten individuals, aged between 7 months and 15 years, were identified, and the starting dose was not adjusted for age. There were no episodes of bleeding, but there was a higher rate of recurrence (10%), which may be explained by the need to maintain central venous access . Other studies have confirmed the efficacy and safety of other LMWHs, such as enoxaparin and dalteparin .…”

Section: Discussionmentioning

confidence: 81%

Evaluation of the age‐dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis

Musgrave

Webber

Murphy

et al. 2017

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Background The recommended starting doses of tinzaparin for the treatment of thrombosis in children have not previously been validated. There are few data to support the efficacy and safety of once-daily tinzaparin dosing in children with thrombosis. Objectives To investigate the use of tinzaparin for the treatment of childhood thrombosis, and to evaluate the age-dependent dosing recommendations and define outcomes in terms of efficacy and safety. Methods This was a retrospective cohort study of children aged 0 to < 16 years treated for thrombosis at a large teaching hospital in the UK between 2008 and 2015. Medical records were reviewed to evaluate tinzaparin dosing, anti-activated factor X (FXa) levels, and patient outcomes. Results Seventy-nine children were identified as having received tinzaparin. Dosing information was available for 57. Younger children required higher doses to reach a therapeutic level. The therapeutic dose requirement varied within age groups, supporting the use of anti-FXa monitoring. Over a median follow-up of 35 months, there were 13 (16%) bleeding episodes (two major; seven clinically relevant but non-major; and four minor). There were two (3%) recurrent episodes of thrombosis. Children were treated for a median duration of 3 months, and the majority (86%) remained on tinzaparin for the duration of their anticoagulant therapy. Conclusion Once-daily tinzaparin is a safe and effective treatment for childhood thrombosis, with rates of recurrence and bleeding similar to those for other anticoagulants used in children. The recommended starting doses are appropriate, but anti-FXa monitoring may be required, owing to interindividual variability in the therapeutic dose requirement.

show abstract

Section: Discussionmentioning

confidence: 81%

Evaluation of the age‐dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis

Musgrave

Webber

Murphy

et al. 2017

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Given that unmodified heparin is known to interact with several hundred proteins (Ori et al, 2008), many of them involved in cell signalling and regulation, it is perhaps surprising that heparin administration does not elicit more side-effects in patients undergoing anticoagulant therapy (Cestac et al, 2003;Quinlan et al, 2012). While this is encouraging for those aiming to develop alternative treatments employing a heparin scaffold, it does present something of a puzzle, and the explanation may lie in the interconnected nature of these signalling and regulatory systems.…”

Section: Discussionmentioning

confidence: 99%

Heparin derivatives for the targeting of multiple activities in the inflammatory response

Veraldi

Hughes

Rudd

et al. 2015

Carbohydrate Polymers

View full text Add to dashboard Cite

An attractive strategy for ameliorating symptoms arising from the multi-faceted processes of excessive and/or continual inflammation would be to identify compounds able to interfere with multiple effectors of inflammation. The well-tolerated pharmaceutical, heparin, is capable of acting through several proteins in the inflammatory cascade, but its use is prevented by strong anticoagulant activity. Derivatives of heparin involving the periodate cleavage of 2,3 vicinal diols in non-sulfated uronate residues (glycol-split) and replacement of N-sulphamido- with N-acetamido- groups in glucosamine residues, capable of inhibiting neutrophil elastase activity in vitro, while exhibiting attenuated anticoagulant properties, have been identified and characterised. These also interact with two other important modulators of the inflammatory response, IL-8 and TNF-alpha. It is therefore feasible in principle to modulate several activities, while minimising anticoagulant side effects, providing a platform from which improved anti-inflammatory agents might be developed.

show abstract

Anticoagulation in patients with acute kidney injury undergoing kidney replacement therapy

et al. 2021

View full text Add to dashboard Cite

Tinzaparin Is Safe and Effective in the Management of Hemodialysis Catheter Thrombosis

Cited by 6 publications

References 4 publications

Evaluation of the age‐dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis

Evaluation of the age‐dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis

Heparin derivatives for the targeting of multiple activities in the inflammatory response

Anticoagulation in patients with acute kidney injury undergoing kidney replacement therapy

Contact Info

Product

Resources

About